---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-347957"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2026-08-13T12:15:15+00:00"
generated_at: "2026-08-13T12:20:17.227512+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Candel Q2 net loss $38.9M; BLA for prostate cancer drug planned Q4 2026

## Summary
- Net loss $38.9M in Q2 2026 vs $4.8M in Q2 2025, including $12.2M net other expense from warrant liabilities.
- R&D expenses $19.8M (vs $7.0M YoY); G&A $6.9M (vs $4.2M YoY).
- Cash and equivalents $201.6M as of June 30, 2026; expected to fund operations into Q1 2028.
- BLA submission for aglatimagene in localized prostate cancer planned Q4 2026; potential U.S. launch in 2027 if approved.
- Phase 3 data in The Lancet Oncology showed 39% improvement in PCa-specific DFS at 58 months; Mark Sims appointed CCO.

## SEC filing metadata
- accession: 0001193125-26-347957
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2026-08-13T12:15:15+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000119312526347957/0001193125-26-347957-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000119312526347957/cadl-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-347957
- JSON: https://secwatch.observer/filing/0001193125-26-347957.json
- Plain text: https://secwatch.observer/filing/0001193125-26-347957.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.